Screener
Immunome IMNM G&A
G&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Collaboration revenue | — | $2,926 |
| Operating expenses: | ||
| Research and development | 46,381 | 36,872 |
| General and administrative | 12,950 | 10,690 |
| Total operating expenses | 59,331 | 47,562 |
| Loss from operations | (59,331) | (44,636) |
| Interest income | 5,492 | 2,996 |
| Net loss | $(53,839) | $(41,640) |
Item 1. Financial Statements.
FAQ
- What is Immunome's G&A?
- Immunome (IMNM) reported G&A of $12.95M in Q1 2026.
- How has Immunome's G&A changed year-over-year?
- Immunome's G&A increased by 21.1% year-over-year, from $10.69M to $12.95M.
- What is the long-term trend for Immunome's G&A?
- Over 4 years (2021 to 2025), Immunome's G&A has grown at a 40.9% compound annual growth rate (CAGR), from $11.09M to $43.77M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Immunome's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude